Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24488175 | 0.83 | MEN1 (0.35) | KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL21251673 | 0.80 | P2RX3 (0.35) | P2RX3P2RX2JAK2JAK1TYK2 | |
| SCHEMBL21251963 | 0.78 | PDE4B (0.35) | KDM4EALDH1A1 | |
| SCHEMBL24488280 | 0.77 | FGFR1 (0.33) | P2RX3P2RX2ALDH1A1TSHR | |
| SCHEMBL20331075 | 0.73 | MEN1 (0.33) | KDM4E | |
| SCHEMBL21252281 | 0.68 | ERN1 (0.36) | KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL20331456 | 0.66 | MEN1 (0.41) | KDM4E | |
| SCHEMBL13736042 | 0.63 | NUDT1 (0.39) | P2RX3P2RX2KDM4EALDH1A1TSHR | |
| SCHEMBL20330599 | 0.63 | MEN1 (0.38) | TSHR | |
| SCHEMBL24488218 | 0.62 | FGFR1 (0.34) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |